Novo Nordisk A/S (NVO) News Today

Novo Nordisk A/S (NYSE: NVO) is being pulled in opposing directions as encouraging clinical and cardiovascular data compete with renewed concerns about Eli Lilly’s product pipeline and Novo’s ability to sustain growth beyond Ozempic and Wegovy.

• Positive Sentiment: Novo reported real-world evidence that patients with type 2 diabetes who increased Ozempic (semaglutide) to 2 mg had a 6% lower risk of major cardiovascular events than patients who switched to Eli Lilly’s Mounjaro (tirzepatide). The findings strengthen Ozempic’s clinical and commercial positioning, although the analysis was retrospective and observational. Novo says Ozempic shows lower risk of cardiovascular events compared to Lilly's Mounjaro
• Positive Sentiment: Novo licensed global rights to HRS-1596, a phase 1-ready once-weekly oral GLP-1/GIP drug from China’s Hengrui Pharmaceuticals. The deal could reach $2.6 billion, including a $300 million upfront payment and royalties, giving Novo another potential oral obesity and diabetes treatment. However, the asset remains at an early development stage. China's Hengrui inks up to $2.6 billion deal with Novo Nordisk for obesity drug
• Positive Sentiment: Phase 3 REIMAGINE 5 data showed the lower-dose CagriSema combination produced substantial weight loss in adults with type 2 diabetes, supporting hopes that the candidate can improve Novo’s competitive position against Lilly’s tirzepatide franchise. Novo Nordisk Just Beat Lilly in a Trial
• Neutral Sentiment: Novo is also pursuing longer-acting delivery technology through a collaboration with Nanexa, potentially enabling monthly dosing across obesity, diabetes and related indications. The opportunity could support future growth, but development and regulatory uncertainty remain significant. Novo Nordisk Licenses Nanexa's PharmaShell
• Positive Sentiment: Novo continues its share-repurchase program, part of a broader plan to buy back up to DKK 15 billion over 12 months. Buybacks can support earnings per share and signal management confidence in the valuation. Novo Nordisk share repurchase programme
• Negative Sentiment: Eli Lilly countered with analysis claiming its oral obesity drug Foundayo delivered greater weight loss and better blood-sugar control than higher-dose Ozempic tablets. The comparison relies on existing, non-head-to-head studies, but it reinforces investor concerns about intensifying competition in oral GLP-1 treatments. Lilly touts Foundayo advantage over Novo's Ozempic pill